Fluorouracil Treatment Via Colon for Colorectal Cancer

Fluorouracil (5-FU) is a commonly used drug for colorectal cancer (CRC). Thermosensitive hydrogel presents a promising carrier for 5-FU to address challenges encountered with traditional administration methods. We propose an integrated approach utilizing colonic transendoscopic enteral tubing to cover the entire colon flexibly, coupled with a thermo-sensitive gel to enhance the adhesion of 5-FU. This clinical trial aims to assess the feasibility, safety, and efficacy of this approach for treating CRC.

Trial Details

NCT ID
NCT06385418
Phase
PHASE2
Sponsor
The Second Hospital of Nanjing Medical University
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Colonic local administration of fluorouracil with enhanced adhesion
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • Chinese individuals aged 18 to 75 years, both male and female;
  • Histologically confirmed diagnosis of colorectal cancer with measurable primary lesion according to RECIST 1.1;
  • ECOG performance status ≤2;
  • Expected survival of more than 3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →